The DEEp SEA Study (LP352-302) is a global Phase 3 double-blind, placebo-controlled clinical trial to evaluate the efficacy of bexicaserin in Dravet syndrome as assessed by countable motor ...

The independent Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase 3 DRAGON trial without modifications, indicating confidence in the trial's design and preliminary results.

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a ...

LIBERTYVILLE, Ill.--(BUSINESS WIRE)--Pharma Logistics (www.pharmalogistics.com), a leader in the pharmaceutical compliance and reverse distribution industry, welcomes David A. Hargraves as its new ...